Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2024 | 2025 | |
|---|---|---|
| Revenue | $441.0K | $59.0K |
| Cost of revenue | $27.3M | $0 |
| Gross profit | −$26.8M | $0 |
| Gross margin | -6084.8% | 0.0% |
| R&D | $24.4M | $50.1M |
| Operating income | −$68.5M | −$72.9M |
| EBITDA | −$31.5M | $344.0K |
| Net income | −$35.1M | −$78.3M |
| Net margin | -7965.8% | -132642.4% |
| EPS (diluted) | -3.34 | -5.84 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CERC.
No tracked institution reports a position in CERC as of their last filing.
No one on the platform has traded CERC yet.
| $38M |
| — |
| MGTAMagenta Therapeutics, Inc. | $0.70 | -7.74% | $42M | — |
| ORKAOruka Therapeutics, Inc. | $92.49 | +2.09% | $3.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.